Posted by Michael Wonder on 11 Dec 2022
Clinical Disease Activity Index (CDAI) first choice when assessing treatment effects
9 December 2022 - A team led by IQWiG authors systematically compares instruments for measuring the treatment effects of disease-modifying anti-rheumatic drugs on a broad database.
Reducing disease activity and, if possible, achieving almost complete freedom from symptoms (remission) is the primary goal of treatment in rheumatoid arthritis.
